Fernández MJE, Díaz VE

Language: Spanish
References: 15
Page: 1345-1359
PDF size: 964.72 Kb.

ABSTRACT

Introduction: pulmonary hypertension is a common finding in heart failure. The use of sildenafil in these cases is a common practice, but still controversial due to the limited number of studies carried out.
Objective: to compare echocardiographic variables of pulmonary hemodynamics, in patients with left ventricular systolic dysfunction and severe secondary pulmonary hypertension, before and after the use of sildenafil.
Materials and methods: a cohort study was led, including 19 patients; a two-year follow-up was carried out. Clinical, laboratory and echocardiographic variables were analyzed. The main pulmonary hemodynamics variables were evaluated before the use of sildenafil and 12 weeks after its indication. A survival curve was performed at the end of the follow-up. The statistical significance level used was p < 0.05.
Results: the average age was 56.16 ± 15.77 years, and male sex predominated with 73.3 %. Survival at the end of the follow up was 78.9 %. The main echocardiographic variables of pulmonary hemodinamics showed a significant reduction at 12 weeks of treatment with sildenafil. The survival of patients with a 25 % reduction in pulmonary pressures in the echocardiogram performed at 12 weeks of treatment was greater at the end of the study (100 % vs 33 %, log-rank test p = 0.001).
Conclusions: after using sildenafil, a significant reduction of pulmonary hemodynamics variables was found in the evolutionary echocardiogram. Survival was higher in patients who had this reduction.

REFERENCES

1. Ponikowski P, Voors AV, Anker SD, et al. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Rev Esp Cardiol [Internet]. 2016 [citado 04/02/2020];69(12):1167-85. Disponible en: Disponible en: https://www.revespcardiol.org/es-guia-esc-2016-sobre-el-articulo-S0300893216305541

2. Gómez López E. Hipertensión pulmonar asociada a enfermedad cardiaca izquierda: enfoque diagnóstico y terapéutico. Rev Colomb Cardiol [Internet]. 2017 [citado 08/05/2020];24(S1):55-64. Disponible en: Disponible en: http://dx.doi.org/10.1016/j.rccar.2017.08.009

3. McLaughlin VV, Sanjiv J, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976-97. Citado en PubMed; PMID: 25953750.

4. Galie N, Humberta M, Vachieryc JL, et al. Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. Rev Esp Cardiol [Internet]. 2016 [citado 12/06/2019];69(2). Disponible en: Disponible en: http://dx.doi.org/10.1016/j.recesp.2016.01.002

5. Barnett CF, DeMarco T. Pulmonary hypertension associated with left-sided heart disease. Heart Fail Clin. 2012;8:447-59. Citado en PubMed; PMID: 22748905.

6. Curotto JL, Paragano AJ, Machado RA, et al. El sildenafil mejora la capacidad de ejercicio en pacientes con insuficiencia cardíaca crónica. Rev Argent Cardiol [Internet]. 2010 [citado 05/06/2020];78:308-14. Disponible en: Disponible en: http://www.redalyc.org/articulo.oa?id=30532692007

7. Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail [Internet]. 2011 [citado 05/06/2019];4:8-17. Disponible en: Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.110.944694

8. Giannetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med [Internet]. 2014 [citado 05/06/2019];12:185. Disponible en: Disponible en: https://www.semanticscholar.org/paper/Is-chronic-inhibition-of-phosphodiesterase-type-5-A-Giannetta-Feola/1f1847050939e12d606fd5c2b2814e648ddc6404

9. Díaz-Toro F, Nazzal C, Verdejo H. Incidencia y letalidad intrahospitalaria por insuficiencia cardiaca en Chile: ¿Existen diferencias por sexo? Rev Med Chile [Internet]. 2017 [citado 05/05/2020];145:703-9. Disponible en: Disponible en: https://scielo.conicyt.cl/pdf/rmc/v145n6/0034-9887-rmc-145-06-0703.pdf

10. Pellegrini P, Rossi A, Pasotti M. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest [Internet]. 2014 [citado 05/05/2020];145(5):1064-70. Disponible en: Disponible en: https://journal.chestnet.org/article/S0012-3692(15)34599-2/references

11. Kirchof P, Benussi S, Kotecha D, et al. Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. Rev Esp Cardiol [Internet]. 2016 [citado 05/05/2020];70(1):431-84. Disponible en: Disponible en: https://www.revespcardiol.org/es-guia-esc-2016-sobre-el-articulo-S0300893216306625

12. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with betablockers: results from COMET. Eur Heart J. 2005;26(13):1303-8. Citado en PubMed; PMID: 15767288.

13. Coria P. Fallo agudo del ventrículo derecho. Insuf Card [Internet]. 2018 [citado 05/05/2020];13(4):170-85. Disponible en: Disponible en: http://www.insuficienciacardiaca.org/pdf/v13n4_18/v13n4a3.pdf

14. Cursack G, Núñez C, Coronel ML, et al. Disfunción grave de ventrículo derecho por ecocardiografía en hipertensión arterial pulmonar: prevalencia, predictores clínicos, ecocardiográficos y tratamiento. Insuf Card [Internet]. 2017 [citado 05/05/2020]; 12(1):16-23. Disponible en: Disponible en: http://sedici.unlp.edu.ar/handle/10915/53167

15. Pérez D, Fernández A, Estigarribia J, et al. Estimación de la presión arterial pulmonar mediante ecocardiografía. Rev Urug Cardiol [Internet]. 2019 [citado 06/06/2020];34:270-83. Disponible en: Disponible en: http://www.scielo.edu.uy/pdf/ruc/v34n3/1688-0420-ruc-34-03-109.pdf